Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma

Melanoma is characterized by oncogenic mutations in pathways regulating cell growth, proliferation, and metabolism. Greater than 80% of primary melanoma cases harbor aberrant activation of the mitogen-activated protein kinase kinase/extracellular-signal-regulated kinase (MEK/ERK) pathway, with oncog...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolfe, Zachary, Friedland, Julie C., Ginn, Sarah, Blackham, Aaron, Demberger, Lauren, Horton, Morgan, McIntosh, Alyson, Sheikh, Hina, Box, Jessica, Knoerzer, Deborah, Federowicz, Bryan, Stuhlmiller, Timothy J., Shapiro, Mark, Nair, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Short Communications: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245552/
https://www.ncbi.nlm.nih.gov/pubmed/35551160
http://dx.doi.org/10.1097/CMR.0000000000000830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245552/
https://www.ncbi.nlm.nih.gov/pubmed/35551160
http://dx.doi.org/10.1097/CMR.0000000000000830

Ejemplares similares